(RTTNews) - Alterity Therapeutics (ATHE, ATH.AX) announced that it has received positive regulatory feedback following a Type C Meeting with the U.S. Food and Drug Administration (FDA) regarding its planned Phase 3 development program for ATH434 in Multiple System Atrophy (MSA).
The Type C Meeting is part of Alterity's multidisciplinary strategy to align with the FDA on readiness to initiate a pivotal Phase 3 trial in MSA. The company reported that it received written feedback supporting its plans related to both the clinical pharmacology and non-clinical development aspects of the program, reinforcing confidence in moving forward with the next stage of clinical testing.
ATH.AX was trading on the Australian Securities Exchange at A$0.0080, showing no change from the previous session.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
